In this article
FDA Approval for High-Risk and Metastatic TNBC
August 2021: Pembrolizumab (Keytruda, Merck) was approved by the FDA for high-risk, early-stage triple-negative breast cancer (TNBC) as a neoadjuvant treatment in combination with chemotherapy, and later as a single agent as adjuvant treatment following surgery.
Pembrolizumab in conjunction with chemotherapy was also given regular approval by the FDA for patients with locally recurrent unresectable or metastatic TNBC whose tumours express PD-L1 (Combined Positive Score [CPS] 10) as assessed by an FDA-approved test. In November 2020, the FDA gave pembrolizumab expedited approval for this indication.
The neoadjuvant and adjuvant approvals, as well as the confirmatory trial for the accelerated approval, were based on the following trial.
KEYNOTE-522 Trial Design and Treatment Protocol
In KEYNOTE-522 (NCT03036488), a randomised, multicenter, double-blind, placebo-controlled trial involving 1174 patients with newly diagnosed previously untreated high-risk early-stage TNBC (tumour size >1 cm but 2 cm) and continued adjuvant treatment with pembrolizumab as a single agent, the efficacy of pembrolizumab in combination with neoadjuvant chemotherapy followed by surgery and continued Patients were included regardless of PD-L1 expression in their tumours.
Pembrolizumab in conjunction with chemotherapy or placebo in combination with chemotherapy were given to patients in a 2:1 ratio. The chemotherapy protocol is detailed in the drug label, which is linked below.
Efficacy Outcomes: pCR and Event-Free Survival
The pathological complete response (pCR) rate and event-free survival were the primary efficacy outcome metrics (EFS). Patients who received pembrolizumab in conjunction with chemotherapy had a pCR rate of 63 percent (95 percent CI: 59.5, 66.4), compared to 56 percent (95 percent CI: 50.6, 60.6) for patients who got chemotherapy alone. The proportion of patients who had an EFS episode was 123 (16%) and 93 (24%), respectively (HR 0.63; 95 percent CI: 0.48, 0.82; p=0.00031).
Adverse Reactions and Dosage Administration
Fatigue/asthenia, nausea, constipation, diarrhoea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, and insomnia were the most common adverse reactions reported in approximately 20% of patients in trials of pembrolizumab in combination with chemotherapy.
Pembrolizumab is given as an intravenous infusion over 30 minutes at a dose of 200 mg every three weeks or 400 mg every six weeks for TNBC. For neoadjuvant treatment, pembrolizumab is given in combination with chemotherapy for 24 weeks, and then as a single agent for adjuvant treatment for up to 27 weeks.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Related Articles
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.